Phase II drug metabolizing enzymes

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F10%3A10213185" target="_blank" >RIV/61989592:15110/10:10213185 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Phase II drug metabolizing enzymes

Popis výsledku v původním jazyce

Phase II biotransformation reactions generally serve as a detoxifying step in drug metabolism. Phase II drug metabolising enzymes are mainly transferases. This review covers the major phase II enzymes: UDP-glucuronosyltransferases, sulfotransferases, N acetyltransferases, glutathione S-transferases, thiopurine S-methyltransferase and catechol O-methyltransferase. The focus is on the presence of various forms, on tissue and cellular distribution, on the respective substrates, on genetic polymorphism andfinally on the interspecies differences in these enzymes. Phase II drug metabolizing enzymes play an important role in biotransformation of endogenous compounds and xenobiotics to more easily excretable forms as well as in the metabolic inactivation of pharmacologically active compounds. Reduced metabolising capacity of Phase II enzymes can lead to toxic effects of clinically used drugs. Gene polymorphism/ lack of these enzymes may often play a role in several forms of cancer.

Název v anglickém jazyce

Phase II drug metabolizing enzymes

Popis výsledku anglicky

Phase II biotransformation reactions generally serve as a detoxifying step in drug metabolism. Phase II drug metabolising enzymes are mainly transferases. This review covers the major phase II enzymes: UDP-glucuronosyltransferases, sulfotransferases, N acetyltransferases, glutathione S-transferases, thiopurine S-methyltransferase and catechol O-methyltransferase. The focus is on the presence of various forms, on tissue and cellular distribution, on the respective substrates, on genetic polymorphism andfinally on the interspecies differences in these enzymes. Phase II drug metabolizing enzymes play an important role in biotransformation of endogenous compounds and xenobiotics to more easily excretable forms as well as in the metabolic inactivation of pharmacologically active compounds. Reduced metabolising capacity of Phase II enzymes can lead to toxic effects of clinically used drugs. Gene polymorphism/ lack of these enzymes may often play a role in several forms of cancer.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FR - Farmakologie a lékárnická chemie

OECD FORD obor

—

Projekt

<a href="/cs/project/GD303%2F09%2FH048" target="_blank" >GD303/09/H048: Molekulární mechanismy vybraných patologických procesů v buňce</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2010

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Biomedical Papers

ISSN

1213-8118

e-ISSN

—

Svazek periodika

154

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

14

Strana od-do

—

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—